| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 5, 2025 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that Mary W. Yamashita, MD will serve as Medical Advisor to the Company. In her role as QT Imaging Medical Advisor, Dr. Yamashita will provide strategic advisory and development support across several key areas, including clinical interpretation standards, structured reporting frameworks, training architecture, and reader study design. Her expertise will be instrumental in optimizing clinical integration and user experience, ensuring that the Company's technologies not only
The Company's first CPT code becomes effective January 1, 2027, enables billing and opening new commercial opportunities with hospital accounts QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that the American Medical Association (AMA) CPT (Current Procedural Terminology) Editorial Panel has approved a new Category III CPTTM code for 3D quantitative transmission volumetric ultrasound tomography of the breast. The new Category III code, X579T, represents a significant milestone in the clinical and commercial advancement
Generated Record Revenue of $8.3 Million in Q4 2025, up 97% versus Q3 2025 Shipped Record 17 Scanners in Q4 2025 and 40 in 2025, up from 12 Scanners Shipped in 2024 Exceeded 2025 Sales Outlook, Delivering Revenue of $18.9 Million Relisted on Nasdaq Less Than One Year After Leaving the Exchange Continues to Pivot from a Scanner Company to a SaaS and Biomarker-Driven Medical Imaging Franchise QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company") a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announces preliminary unaudited financial results for the fourth quarter and full year
8-K - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)
8-K - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)
SCHEDULE 13G - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)
4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)
4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)
4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)
4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)
4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)
4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)
Generated Scanner Sales Revenue of $1.4M with 56% Gross Margin in the First Quarter of 2024, Since the Company Became Public on March 4th Streamlined Business Model via Strategic Sales and Distribution Partnership in USA Reported in Academic Radiology the Results of a Second Blinded Screening Trial That Found That QTI Technology Is Similarly Effective as Digital Breast Tomosynthesis (DBT) or 3D Mammography Company Completed Merger with GigCapital5 QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the first qu
Generated Record Revenue of $8.3 Million in Q4 2025, up 97% versus Q3 2025 Shipped Record 17 Scanners in Q4 2025 and 40 in 2025, up from 12 Scanners Shipped in 2024 Exceeded 2025 Sales Outlook, Delivering Revenue of $18.9 Million Relisted on Nasdaq Less Than One Year After Leaving the Exchange Continues to Pivot from a Scanner Company to a SaaS and Biomarker-Driven Medical Imaging Franchise QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company") a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announces preliminary unaudited financial results for the fourth quarter and full year
Generated Scanner Sales Revenue of $0.9 Million with 65% Gross Margin in the Third Quarter of 2024 The Company Successfully Completed the Engineering and Clinical Feasibility Study with its Strategic Partner The Company Announced Entering into Favorable Amendments to Its $10 Million Convertible Promissory Note with YA II PN, Ltd. The Company Announced Insiders PIPE investment of $2.56 Million, fully funded by the QTI Board of Directors members and their Affiliates QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results
Generated Scanner Sales Revenue of $1.7 Million with 51% Gross Margin in the Second Quarter of 2024 The Company Continues to Make Progress in the Engineering and Clinical Feasibility Study with its Strategic Partner Signed a U.S. Exclusive Distribution Agreement Announced Partnership with the University of Oklahoma and OU Health Stephenson Cancer Center to Improve Precision in Cancer Detection and Treatment QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the second quarter of 2024. "QT Imaging's team comp
SC 13D/A - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)
SC 13G - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)
SC 13D/A - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)